マルチオミクスサービス市場- 世界の産業規模、シェア、動向、機会、予測、サービス別、タイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030F予測

マルチオミクスサービスの世界市場規模は2024年に11億6,000万米ドル、2030年には30億4,000万米ドルに達すると予測、CAGRは17.39%。

世界のマルチオミクスサービス市場は、ヘルスケアシステム、研究機関、製薬会社が、精密医療や個別化医療ソリューションのニーズの高まりに対応するため、統合オミックスアプローチをますます採用するようになり、大きな拡大を経験しています。ゲノミクス、トランスクリプトミクス、プロテオミクス、メタボロミクス、エピゲノミクスを組み合わせたマルチオミクスサービスは、生物学的システムと疾病メカニズムの包括的な理解を可能にします。これらのアプローチは、創薬、バイオマーカーの同定、標的療法の開発において重要となってきています。慢性疾患や遺伝性疾患の蔓延、高度な診断ソリューションに対する需要の高まり、学術機関と業界関係者の強力な連携が、マルチオミクスサービスの採用を後押ししています。次世代シーケンシング、質量分析、バイオインフォマティクスの技術的進歩により、これらのサービスの効率性と拡張性は著しく向上し、複数のエンドユーザー部門にわたってより利用しやすくなっています。

マルチオミクスサービス市場の成長は、プレシジョン・ヘルスケアへの注目の高まり、疾患の早期発見の必要性、臨床上の意思決定におけるオミックスデータの利用の増加など、複合的な要因によってもたらされます。製薬企業やバイオテクノロジー企業は、医薬品開発パイプラインの合理化、離脱率の低減、臨床試験の成功率向上のためにマルチオミクスを活用しています。高度なバイオインフォマティクス・プラットフォームと人工知能の統合は、より正確なデータ解釈を可能にし、疾患プロファイリングと患者層別化の飛躍的進歩につながっています。政府や民間投資家からの戦略的提携や資金援助は、技術革新を加速し、サービスの展望を広げています。さらに、標的治療薬の規制当局による承認に後押しされたコンパニオン診断薬の採用拡大が、マルチオミクスサービスの需要をさらに高めています。これらのツールは、特定の治療に適した患者群を特定する上で中心的な役割を果たすからです。

有望な成長見通しとは裏腹に、市場は拡大のペースに影響を与えかねない課題に直面しています。特に複数のデータセットを統合する場合、マルチオミクス研究に関連する高いコストは、小規模の研究機関や新興経済国にとって経済的な負担が懸念されます。大規模なオミックス研究では、高度な分析ツールや熟練した専門家による解釈を必要とする膨大なデータセットが生成されるため、データの複雑性や相互運用性の問題は依然として大きなハードルとなっています。データのプライバシーに関する懸念や、研究室間で標準化されたプロトコルの欠如が、普及をさらに複雑にしています。とはいえ、こうした課題は技術革新の機会も生み出しています。各社は、よりコスト効率の高いプラットフォーム、クラウドベースのデータソリューション、分析を簡素化しスケーラビリティを向上させる統合ソフトウェアを開発しているからです。バイオインフォマティクス、人工知能、自動化の継続的な進歩により、市場はこれらの障壁の多くを克服し、今後数年間でヘルスケアと研究におけるマルチオミクスの普及への道を開くと期待されています。

市場促進要因

複雑な疾患の調査拡大

主な市場課題

マルチオミクス技術の高コスト

主な市場動向

データ統合におけるAIと機械学習

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のマルチオミクスサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • サービス別（調査サービス、データ分析サービス）
  • タイプ別（単一細胞マルチオミクス、バルクマルチオミクス）
  • 用途別（バイオマーカー探索、創薬開発、合成生物学、その他）
  • エンドユーザー別（学術調査機関、製薬・バイオテクノロジー企業、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のマルチオミクスサービス市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のマルチオミクスサービス市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のマルチオミクスサービス市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のマルチオミクスサービス市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのマルチオミクスサービス市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Multiomics Services Market was valued at USD 1.16 Billion in 2024 and is expected to reach USD 3.04 Billion by 2030 with a CAGR of 17.39%. The Global Multiomics Services Market is experiencing significant expansion as healthcare systems, research institutions, and pharmaceutical companies increasingly adopt integrated omics approaches to address the growing need for precision medicine and personalized healthcare solutions. Multiomics services, which combine genomics, transcriptomics, proteomics, metabolomics, and epigenomics, allow for a comprehensive understanding of biological systems and disease mechanisms. These approaches are becoming critical in drug discovery, biomarker identification, and the development of targeted therapies. The growing prevalence of chronic and genetic diseases, rising demand for advanced diagnostic solutions, and strong collaborations between academic institutions and industry players are pushing the adoption of multiomics services. With technological advancements in next-generation sequencing, mass spectrometry, and bioinformatics, the efficiency and scalability of these services have improved significantly, making them more accessible across multiple end-user sectors.

The growth of the multiomics services market is driven by a combination of factors, including the rising focus on precision healthcare, the need for early disease detection, and the increasing use of omics data in clinical decision-making. Pharmaceutical and biotechnology companies are leveraging multiomics to streamline drug development pipelines, reduce attrition rates, and enhance the success of clinical trials. The integration of advanced bioinformatics platforms and artificial intelligence is enabling more accurate data interpretation, leading to breakthroughs in disease profiling and patient stratification. Strategic collaborations and funding support from governments and private investors are accelerating innovation and expanding the service landscape. In addition, the rising adoption of companion diagnostics, driven by regulatory approval for targeted therapies, is further creating demand for multiomics services, as these tools play a central role in identifying the right patient groups for specific treatments.

Despite the promising growth prospects, the market faces challenges that could impact its pace of expansion. High costs associated with multiomics studies, particularly when integrating multiple datasets, pose affordability concerns for smaller institutions and emerging economies. Data complexity and interoperability issues remain significant hurdles, as large-scale omics studies generate massive datasets requiring sophisticated analytical tools and skilled professionals for interpretation. Concerns over data privacy and the lack of standardized protocols across laboratories further complicate widespread adoption. Nonetheless, these challenges also create opportunities for innovation, as companies are developing more cost-efficient platforms, cloud-based data solutions, and integrated software to simplify analysis and improve scalability. With continuous advancements in bioinformatics, artificial intelligence, and automation, the market is expected to overcome many of these barriers, paving the way for widespread adoption of multiomics in healthcare and research over the coming years.

Key Market Drivers

Growing Research in Complex Diseases

Rising research into complex diseases continues to drive strong momentum in the Global Multiomics Services Market. Conditions such as cancer, neurodegenerative diseases, cardiovascular disorders, autoimmune illnesses, and rare genetic syndromes involve multifaceted biological pathways that cannot be fully described by single-layer analyses. By integrating genomics, transcriptomics, proteomics, epigenomics, and metabolomics, multiomics enables an in-depth view of disease mechanisms, facilitating discovery of novel biomarkers and therapeutic targets. For example, in September 2023 the U.S. National Institutes of Health announced a USD 50.3 million investment over five years to establish the Multi-Omics for Health and Disease Consortium, funding diverse disease studies and scalable workflows for integrating complex datasets. This type of strategic support underscores how critical multiomics has become in tackling intricate health challenges.

Pharmaceutical and biotech firms are turning increasingly to multiomics strategies to bolster drug development efforts in complex disease areas. Heterogeneous patient responses and disease subtypes demand precision; multiomics data helps stratify patient groups, predict outcomes, and optimize clinical trial design. This approach reduces failure rates and accelerates time-to-market for new therapies. Integration with advanced bioinformatics and AI accelerates interpretation of massive datasets, empowering accelerated insights in oncology, neurological disorders, chronic and metabolic conditions. Strong interest among healthcare providers and research organizations in these capabilities continues to bolster demand for multiomics services.

Academic institutions, public-private partnerships, and government agencies worldwide are pouring resources into large-scale multiomics projects focused on elucidating complex disease biology. Availability of funding and infrastructure from agencies such as the NIH helps drive cross-disciplinary collaborations. As healthcare shifts toward predictive, preventive, and personalized paradigms, multiomics research is increasingly central to that transition. The combination of governmental funding, technological advances in high-throughput platforms, and growing pharmaceutical and academic demand ensures that the study of complex diseases will remain one of the most significant long-term drivers for the multiomics services market.

Key Market Challenges

High Cost of Multiomics Technologies

The Global Multiomics Services Market faces a significant challenge in the form of the high cost associated with multiomics technologies, which limits widespread adoption across both research and clinical settings. The integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics requires highly sophisticated platforms, advanced sequencing technologies, and powerful computational infrastructure capable of handling vast datasets. These resources involve substantial investment in specialized equipment, consumables, and reagents, making multiomics studies cost-prohibitive for many institutions and healthcare providers, especially in resource-constrained environments. Beyond infrastructure, the costs are compounded by the need for skilled professionals who can design experiments, manage complex data pipelines, and perform advanced bioinformatics analysis, often driving up operational expenses.

The expense of large-scale projects becomes even more challenging when multiomics data are applied in clinical research or precision medicine, as validation, regulatory compliance, and data interpretation demand additional financial resources. High costs not only limit accessibility for smaller research institutes and hospitals but also restrict broader patient access to personalized diagnostic and therapeutic solutions that multiomics could enable. This creates a divide between well-funded organizations capable of adopting multiomics and those unable to invest at the required scale, slowing the overall pace of market penetration. Addressing cost-related barriers through technological innovations, more affordable sequencing methods, and scalable cloud-based analytics will be crucial for ensuring that multiomics services can transition from niche applications to mainstream use in global healthcare and life sciences.

Key Market Trends

AI and Machine Learning in Data Integration

The integration of artificial intelligence and machine learning into multiomics services is emerging as a transformative trend, addressing one of the most critical challenges in the field, the complexity and scale of multiomics datasets. Genomic, transcriptomic, proteomic, metabolomic, and epigenomic data generate enormous volumes of information that are difficult to analyze through conventional bioinformatics tools. AI-driven platforms are enabling researchers to uncover hidden patterns, correlate molecular profiles, and predict disease biomarkers with a level of precision and speed that was previously unattainable. Machine learning models are increasingly being applied to classify patient subgroups, identify novel therapeutic targets, and support drug discovery pipelines. The adoption of deep learning techniques allows for the integration of heterogeneous datasets, leading to more comprehensive biological insights and accurate disease modeling.

Pharmaceutical and biotechnology companies are investing in AI-powered analytics to streamline clinical trial design, accelerate target validation, and improve patient stratification for personalized therapies. Cloud-based AI solutions are also gaining prominence, offering scalable infrastructure for large-scale data processing while supporting collaboration across research institutions and healthcare organizations. These innovations are reducing data interpretation bottlenecks, improving reproducibility of results, and making multiomics applications more accessible for both research and clinical use. As AI and machine learning continue to evolve, they are expected to play a pivotal role in shaping the future of multiomics services by enabling more efficient integration, predictive modeling, and translation of omics data into actionable healthcare solutions.

Key Market Players

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

Report Scope:

In this report, the Global Multiomics Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiomics Services Market, By Service:

• Research Services
• Data Analysis Services

Multiomics Services Market, By Type:

• Single-cell Multiomics
• Bulk Multiomics

Multiomics Services Market, By Application:

• Biomarker Discovery
• Drug Discovery & Development
• Synthetic Biology
• Others

Multiomics Services Market, By End User:

• Academic & Research Institutes
• Pharmaceutical and Biotechnology Companies
• Others

Multiomics Services Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiomics Services Market.

Available Customizations:

Global Multiomics Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multiomics Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Research Services, Data Analysis Services)
  • 5.2.2. By Type (Single-cell Multiomics, Bulk Multiomics)
  • 5.2.3. By Application (Biomarker Discovery, Drug Discovery & Development, Synthetic Biology, Others)
  • 5.2.4. By End User (Academic & Research Institutes, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Multiomics Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiomics Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Multiomics Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Multiomics Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Multiomics Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Multiomics Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Multiomics Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Multiomics Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Multiomics Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Multiomics Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Multiomics Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multiomics Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Multiomics Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Multiomics Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Multiomics Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Multiomics Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Multiomics Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multiomics Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Multiomics Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Multiomics Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Multiomics Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multiomics Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Multiomics Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Multiomics Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sapient Bioanalytics, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Bio-Techne Corporation
• 15.3. CD Genomics, Inc.
• 15.4. RayBiotech, Inc.
• 15.5. Creative Proteomics, Inc.
• 15.6. Psomagen, Inc.
• 15.7. Source BioScience Ltd.
• 15.8. Persistent Systems Ltd.
• 15.9. Metware Biotechnology Inc.
• 15.10. Dalton Bioanalytics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer